DOCSLIB.ORG

Hlethylenedio~Y-6-[8-6",7"~Methylenedioxy-3"-Methyl-Py-Tetrahydro- Isoqu~Nolyl-L")-Ethyll-4-Rnethyl-3,4,5,6,7,8-Hexahydro-(L~,2':L,2-Benzoquino- Lizine): S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hlethylenedio~Y-6-[8-6 HETEROCYCLES, Yo1 IS. No 1, 198 1 PAPERS OF PROFESSOR TETSUJI KAMETANJ Studies on the Synthesis of Emetine and Related Compounds. VI. A Synthesis of 4',5'-hlethylenedio~y-6-[8-6",7"~methylenedioxy-3"-methyl-py-tetrahydro- isoqu~nolyl-l")-ethyll-4-rnethyl-3,4,5,6,7,8-hexahydro-(l~,2':l,2-benzoquino- lizine): S. Supasawa and T. Kametani, -Yakugaku Zasshi, 65, 372 - 373 (1945). Syntheses of Irnidazoisoquinoline Derivatives. I. Syntheiss of 9.10-Dimetho- xy-3-(p-aminopheny1)-5,6-dihydr0ben2og1y0xa1001ne: T. Kametani and H. Iida, Yakugaku Zasshi, 70, 258 - 261 (1950). Syntheses of Imidazoisoquinoline Derivatives. 11. Synthesis of 9,10-Dimetho- xy-3-veratryl-5,6-dihydrobenzog1yoxalocoline: T. Kametani and H. Iwakata, Yakugaku Zasshi, 70, 261 - 263 (1950). Syntheses of Imidazoisoquinoline Derivatives. 111. Synthesis of 9,10-Di- methoxy-3-safryl-5.6-dihydrobenzaglyoxalli: T. Kametani and H. Iwakata, Yakugaku Zasshi, 70, 263 - 265 (1950). Syntheses of Papaverine Derivatives. I. Synthesis of 1-(3'-Methoxy-4"-hydro- xyphenyl)-3-meth~l-6,7-methylenediaxyisoquinline: T. Karnetani, Yakugaku --,Zasshi -71, 322 - 324 (1951). Syntheses of Imidazoisoquinoline Derivatives. IV. Syntheses of 9,lO-Methyl- enedioxy-3-(4'-nitrophenyl)-5-methyl-5,6-dihydrobenzoglyoxalcoline, 9,10- flethylenedioxy-3-(3',4'-dimethoxyphenyl)-5-methylbenzoglyoxalocoline and 9,lO- Methylenedioxy-3-(3',4'-methylenedioxyphenyl)-5-methyl-5,6-dihydrobenzogly- oxalocoline: T. Kametani, H. Iida, and H. Iwakata, Yakugaku Zasshi, 71, 325 - 329 (1951). Studies on the Syntheses of Aminoisoquinoline Derivatives. I. Sa~anificat ion of Benzyl l-Phenyl-6,7-dirnethoxyisoquinolyl-3-carbmte: T. Kametani, Yakugaku Zasshi, 2, 329 - 331 (1951). Studies on the Syntheses of Aminoisoquinoline Derivatives. 11. A Synthesis of l-Phenyl-3,4-dihydro-4-amino-6,7-dimethoxyisoquinoline Derivatives: T. Kametani, Yakugaku Zasshi, 2, 332 - 335 (195.1). Syntheses of Imidazoisoquinoline Derivatives. V. Synthesis of 9,10-Dimetho- xy-3-nicotinyl-5,6-dihydrobenzoglyoxaloclie: T. Kametani and H. Iida, Yakugaku Zasshi, c,995 - 998 (1951). Syntheses of Imidazoisoquinoline Derivatives. VI. Synthesis of 9,10-Dimetho- xy-3-isonicot~nyl-5,7-dihydrobenzoglyoxalocoline: T. Kametani and H. Iida, Yakugaku Zasshi, 11, 998 - 1000 (1951). Syntheses of Imidazoisoquinoline Derivatives. VII. Synthesis of 9,10-Di- methoxy-3-picolinyl-5,6-dihydrabenzoglyo~1oco1ine: T. Kametani and H. Iida, -Yakugaku Zasshi, 11, 1000 - 1002 (1951). Syntheses of Imidazoisoquinoline Derivatives. VIII. Synthesis of 9,10;9',10'- bis-Dimethoxy-3,3'-(5,6-dihydroben~0glyoxalocline):- T. Kametani and H. Iwakata, Yakugaku Zasshi, 11, 1002 - 1004 (1951). Syntheses of Imidazoisoquinoline Derivatives. IX. Synthesis of 9,10-Di- methoxy-3-(cinchonyl)-5,6-dihydrobenzoglyoxalocoline: T. Kametani and H. Iida, Yakugaku Zasshi, 11, 1004 - 1006 (1951). Syntheses of Pyrimidinoisoquinoline Derivatives. I. Syntheses of (2'-Phenyl- 4'-hydropyrimidino)-1',6';1,2-(3,4-dihydr-6,7-dimethoxyiquinoline): T. Kametani and S. Kano, Xakugaku Zasshi, z,1007 - 1009 (1951). Syntheses of Aminoisoquinoline Derivatives. 111. Synthesis of 1-Phenyl-3,4- dihydro-4-(4'-dimethylaminophenyl)-6,7-dimethoxyioquinoline: T. Kametani and T. Oda, Xaku~akuZasshi, 2,1009 - 1011 (1951). Studies on the Syntheses of Isoquinoline Derivatives. XV. Syntheses of Some Nitro Compounds as Synthetic Materials for Isoquinoline Derivatives: T. Kametani and Y. Masuda, Yakugaku Zasshi, 72, 81 - 85 (1952). Studies on the Syntheses of Isoquinoline Derivatives. XVI. Synthesis of 1- Phenyl-3-veratryl-b,7-dimethoxyisoq~in~line:T. Kametani, Yakugaku Zasshi, -72, 85 - 87 (1952). Studies on the Antibacterial Substances. I. Antibacterial Activities of Iso nicotinic Acid Hydrazide and Isonicotinylglycine Hydrazide: 2. Horii, T. Kametani, and Y. Yamamura, Yakugaku Zasshi, 72, 971 - 972 (1952). Syntheses of Isoquinoline Derivatives. XVII. Studies on the Syntheses of Papaverine Derivatives. (2). Syntheses of I-(2' ,4'-Dihydroxypheny1)- and 1- (3',4'-Dihydroxyphenyl)-3-methyl-6,7-methylenedioxyisoquinoline (Benzylation of 6-Resorcyclic Acid): T. Kametani and S. Kano, Yakugaku Zasshi, 2,1081 1084 (1952). Studies on the Syntheses of Isoquinoline Derivatives. XVIII. Syntheses of Papaverine Derivatives. (3). Synthesis of 1-(3'-Methaxy-4'-hydroxybenzy1)- 3-methyl-6.7-methylenedioxyisoquinoline: T. Kametani and J. Serizawa, Yaku- gaku Zasshi, 72, 1084 - 1087 (1952). HETEROCYCLES, Vol 15, No I, 1981 Studies on the Syntheses of Isoquinoline Derivatives. XIX. Synthesis of 1- Phenyl-3-benzylisoquinaline: T. Kametani, K. Ninomiya, H. Iida, and J. Seri zawa, Yakugaku Zasshi, 72, 1087 - 1090 (1952). Studies on the Syntheses of Isoquinoline Derivatives. XX. A New Method for the Preparation of Isoquinaline Derivatives (1). Reaction of Safrol on Acid Am~dein the Presence of POC13: T. Kametani, Yakugaku Zasshi, 72, 1090 - 1093 (1952). Studies on Antibacterial Substances. 11. Antibacterial Activities of Various Hydrazides for E. tuberculosis in vitro: T. Kametani, Y. Yamamura, and H. Uchida, Yakugaku Zasshi, 2,1093 - 1096 [1952). Studies on the Syntheses of Isoquinaline Derivatives. XXI. A New Method for the Preparation of Isoquinoline Derivatives (2). Reaction of Methyleugenol on Acid Amide in the Presence of POC13: T. Kametani, Yakugaku Zasshi, 3, 1537 - 1539 (1952). Studies on the Syntheses of Isoquinoline Derivatives. XXII. A New llethod for the Preparation of Isoquinoline Derivatives. (3). Condensation Agents. Mechanism of New Syntheses, and a Synthesis of 3,4-Dihydroneupaverine: T. Kametani and K. Ninomiya, Yakugaku Zasshi, E,1539 - 1541 (1952). Studies on the Syntheses of Isoquinoline Derivatives. XXIII. A New Method for the Preparation of Isoquinoline Derivatives. (4). Reaction of Allyl- benzene Derivatives and Oximes: T. Kametani, Yakugaku Zasshi, 73, 12 - 15 (1953). Syntheses of Thiophene Derivatives. I. Modified Synthesis of 3-Dimethylamino- 1,l-di-(2'-thieny1)hutene-1: T. Kametani and Y. Akazawa, Yakugaku Zasshi, E, 649 - 650 (1953). Studies on the Syntheses of Isoquinoline Derivatives. XXIV. Migration of the Double Band of Isoquinoline Derivatives. (1): T. Kametani and H. Iida, gaku Zasshi, 73, 677 - 680 (1953). Studies on the Syntheses of Isoquinaline Derivatives. XXV. Migration of the Double Bond of Isoquinoline Derivatives. (2): T. Kametani and K. Ninomiya, Yakugaku Zasshi, 13, 681 - 685 (1953). Studies on the Syntheses of Isoquinoline Derivatives. XXVI. A New Method for the Preparation of Isoquinoline Derivatives. (5). Reaction of Various Allylbenzene Derivatives and Aldoximes or Acid Amides: T. Kametani and K. Otsuki, Yakugaku Zasshi, 73, 685 - 687 (1953). Studies on the Syntheses of Isoquinoline Derivatives XXVII. Synthesis of 3-lLlethyl-6,7-methylenedioxy-3,4-dihydroisoquinolyl-1-carboxylicAcid Ethyl Ester: T. Kametani, Yakugaku Kenkyu. 2,451 - 453 (1953). Studies on the Syntheses of Isoqulnoline Derivatives. XXVIII. Synthesis of Papaverine Derivatives. (5): T. Kametani and M. Inagaki, Yakugaku Zasshi, -74, 417 - 419 (1954). Studies on the Syntheses of Isoquinoline Derivatives. XXIX. Synthesis of Papaverine Derivatives. (6): T. Kametani and K. Ohtsuki,Yakugaku Zasshi, 74, 621 - 625 (1954). Studies on the Syntheses of Isoquinoline Derivatives. XXX. Synthesis of Papaverine Derivatives. (7): T. Kametani and M. Inagaki, Yakugaku Zasshi, -74, 1040 - 1041 (1954). Studies on the Syntheses of Isoquinoline Derivatives. XXXI. Synthesis of Furo[3,Z-clpyridine Derivatives: T. Kametani, Y. Ito, and H. Isaka, -Yaku- gaku Zassh~,74, 1298 - 1299 (1954). Studies on the Syntheses of Isoquinoline Derivatives. XXXII. Synthesis of Thieno[3,2-5lpy.ridine Derivatives and Their Pharmacological Action: T. Kametani, Y. Ito, and S. Aonuma, Yakugaku Zasshi, 74, 1301 - 1304 (1954). Studies on the Syntheses of Synthetic Analgesics and Antispasmodics. 11. Synthesis of Procalne Amide Analogs: T. Kametani, T. Katagi, T. Fujiwara, and Y. Akasawa, Yakugaku Kenkyu, 26, 544 - 548 (1954). Studies on the Syntheses of Isoquinoline Derivatives and Their Analogs. XXIII. Mechanism of the Cyclization of 3-Phenylisoquinoline Derivatives: T. Kametani and K. Ohtsuki, Yakugaku Zasshi, 75, 705 - 709 (1955). Studies on the Syntheses of Isoquinoline Derivatives and Their Analogs. XXIV. Pyrimidinoisoquinoline Derivatives. (2): T. Kametani and T. Katagi, Yakugaku --Zasshi, 75, 709 - 713 (1955). The Effects of Benzylamine Derivatives on Bloodvessel and Heart: S. Aonuma, T. Hama, and T. Kametani, Yakugaku Kenkyu, 11, 607 - 611 (1955). Studies on the Syntheses of Heterocyclic Compounds. XLII. Synthesis of Imi- dazoisoquinoline Derivatives. X: H. Iida and T. Kametani, Yakugaku Kenkyu, -27, 774 - 778 (1955). Studies on the Syntheses of Isoquinoline Derivatives and Their Analogs. XXXV. Migration of the Double Bond of Pyrimidinoisoquinolines and Presumption of Their Structures by the Infrared Absorption Spectra: T. Kametani and T. Katagi, Pharm. Bull. (Japan), 3, 253 - 259 (1955). HETEROCYCLES. Vol IS, No I, I98 1 Studies on the Syntheses of Isoquinoline Derivatives and Their Analogs. XXXVI. Deamination of 2'-(p-Aminophenyl)pyrimidinoisoquinoline Derivatives: T. Kametani and T. Katagi, Pharm. Bull. (Japan), 3, 259 - 262 (1955). Studies on the Syntheses of Isoquinoline Derivatives and Their Analogs. XXXVII. A New Method for the Preparation of 1-Substituted 3-Methyl-3,4- dihydroisoquinoline Derivatives by the Reaction of Allylbenzene and Hetero- cyclic Ac~dAmide or Oxime: T. Kametani, K. Ohtsuki, and M. Fukui, Pharm. Bull. (Japan), 3, 263 - 266 (1955). Studies on the Syntheses
Load more

Recommended publications
  • Doxepin Hydrochloride Capsule Mylan Pharmaceuticals Inc.
    DOXEPIN HYDROCHLORIDE- doxepin hydrochloride capsule Mylan Pharmaceuticals Inc. ---------- Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of doxepin or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Doxepin is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients and PRECAUTIONS: Pediatric Use.) DESCRIPTION Doxepin hydrochloride is one of a class of psychotherapeutic agents known as dibenzoxepin tricyclic compounds. The molecular formula of the compound is C19H21NO • HCl having a molecular weight of 315.84. It is a white crystalline powder freely soluble in water, in ethanol (96%), and methylene chloride. It may be represented by the following structural formula: Chemically, doxepin hydrochloride is a dibenzoxepin derivative and is the first of a family of tricyclic psychotherapeutic agents.
    [Show full text]
  • SINEQUAN® (Doxepin Hcl) CAPSULES ORAL CONCENTRATE
    69-2135-00-1 SINEQUAN® (doxepin HCl) CAPSULES ORAL CONCENTRATE DESCRIPTION SINEQUAN® (doxepin hydrochloride) is one of a class of psychotherapeutic agents known as dibenzoxepin tricyclic compounds. The molecular formula of the compound is C19H21NO•HCl having a molecular weight of 316. It is a white crystalline solid readily soluble in water, lower alcohols and chloroform. Inert ingredients for the capsule formulations are: hard gelatin capsules (which may contain Blue 1, Red 3, Red 40, Yellow 10, and other inert ingredients); magnesium stearate; sodium lauryl sulfate; starch. Inert ingredients for the oral concentrate formulation are: glycerin; methylparaben; peppermint oil; propylparaben; water. CHEMISTRY SINEQUAN (doxepin HCl) is a dibenzoxepin derivative and is the first of a family of tricyclic psychotherapeutic agents. Specifically, it is an isomeric mixture of: 1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)ylidene-N,N-dimethyl-, hydrochloride. 1 ACTIONS The mechanism of action of SINEQUAN (doxepin HCl) is not definitely known. It is not a central nervous system stimulant nor a monoamine oxidase inhibitor. The current hypothesis is that the clinical effects are due, at least in part, to influences on the adrenergic activity at the synapses so that deactivation of norepinephrine by reuptake into the nerve terminals is prevented. Animal studies suggest that doxepin HCl does not appreciably antagonize the antihypertensive action of guanethidine. In animal studies anticholinergic, antiserotonin and antihistamine effects on smooth muscle have been demonstrated. At higher than usual clinical doses, norepinephrine response was potentiated in animals. This effect was not demonstrated in humans. At clinical dosages up to 150 mg per day, SINEQUAN can be given to man concomitantly with guanethidine and related compounds without blocking the antihypertensive effect.
    [Show full text]
  • Handbook of Common Poisonings in Children. INSTITUTION Food and Drug Administration (DREW), Washington, D.C
    O DOCUMENT BESUME ED 144 708 PS 099 577 $ ...,, / 1.- . ,TITLE - Handbook of CommOn Poisonings in Children. INSTITUTION Food and Drug Administration (DREW), Washington, D.C. " fEPORT NO , HEW-FDA-707004 pus DATE /6, ' NOTE -114p. ,.. 1 AyAILABLEFRO!! Superintendent of Documents, U.S. Government Printing ..... Office, Washington, D.C. 20402 (Stock No. 017-C12-0024074, $1.50) . EDRS PRICE NF -$0.83 HC-$6.01. Pins Postage. DESCRtPTORS Accident Prevention;*Children;Emergency'SqUad Personnel; *Governm'ent Publications; icGuidaS; Hospital Pe onnel; Pharmacists;- Physicians;_ *Reference Bo ks IDENTtFIERS, *Poisoning ABSTRACT This handbook for physicians, emergency room. personhel and pharmacists lists- the manufacturer, descriptiOn, / toxiaity, symptoms and findings, treatment, and references.for-73 . / poison substances considered by the Subcommittee on 1Ccidental 1 Poisoning of the American-Academi% of'Pediatrics to be most significant in terms of accidental poisoning of.ehildFen.' (BF) 1 *****************************f**************,************************** * .DOcuments acquirNd by ERIC inclUde many inforMal unpublished *. * materials not available from other-sources. ERIC makes every effort * * to obtain the'best copy available. Nevertheless, items of marginal * * reproducibility are often encountered and this affects the quality * *sof the 'microfiche and hardcopy reproddctions ERIC makes available * via the ERIC Document (reproduction Service (EDRS) .EDRS is not . * * responsible for the quality bf the original document. Reproductions * . *.supplied by EDRS, are the best that can beemade from the 'original. ******************41********r****************************************** U.S. DEPARTtAENT OF HEALTH, EDUCATION, AND WELFARE Public vice/Fo©d and Drug Administration 5600Fi Rockville, Maryland 20857 HEW (FDA) 16-7004 , , , Handbook of # ,. Common Poisonings in Children 1976,. 0 r FDA 4,1 . For we by the 044rorinlyndsrot el Deoumenes.
    [Show full text]
  • Study Regarding Photodegradation Processes of Tricyclic Antidepressants and the Toxicity of the Degradation Products
    University of Medicine and Pharmacy Faculty of Pharmacy Department of Pharmaceutical Chemistry STUDY REGARDING PHOTODEGRADATION PROCESSES OF TRICYCLIC ANTIDEPRESSANTS AND THE TOXICITY OF THE DEGRADATION PRODUCTS Author: Scientific guider: Székely Pál Prof. dr. Gyéresi Árpád Depression is classified as a mood disorder that manifests itself through a feeling of sadness, melancholy, and it is often accompanied by anxiety and irritability. This state of mind is characterized by slow thinking, lack of imagination, loss of memory and concentration capacity, the emergence of obsessive ideas (pessimistic and suicidal), as well as psychomotor disturbances, fatigue and restlessness. It requires special psychiatric and pharmaceutical treatment. There are a wide variety of pharmaceutical substances used in the therapy of depression, one of the most important being the group of tricyclic antidepressants (TCAs). TCAs have been used since the early 50s to treat depression, as they were the first group of pharmaceutical substances that were synthesized for this specific purpose. The basic structure of TCA is composed of a linear system consisting of three condensed cycles, which bind to a structure having a side chain N atom of basic character. Based on the basic structure, the classic tricyclic antidepressants can be divided into derivatives of dihydro- dibenzazepine, dibenzazepine, dibenzocycloheptadiene, dibenzoxepin, and dibenzothiophene. In cases of clinical depression, the classic tricyclic compounds have antidepressive, sedative, anxiolytic or stimulant effects. Lately their effectiveness in neuropathic pain treatment has also been recognized. TCAs and their metabolites act on a large number of receptors and their adverse effects are numerous, which is a major impediment in clinical use. In order to induce photochemical skin reactions, the ultraviolet radiation must penetrate to the peripheral capillaries, so that the UV light reaches the absorbing molecule.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.486,437 B2 Rogowski Et Al
    USOO94864-37B2 (12) United States Patent (10) Patent No.: US 9.486,437 B2 Rogowski et al. (45) Date of Patent: *Nov. 8, 2016 (54) METHODS OF USING LOW-DOSE DOXEPIN 5,858.412 A 1/1999 Staniforth et al. FOR THE IMPROVEMENT OF SLEEP 5,866,166 A 2f1999 Staniforth et al. 5.948,438 A 9, 1999 Staniforth et al. (71) Applicants: Pernix Sleep, Inc., Morristown, NJ 5,965,166 A 10, 1999 Hunter et al. (US); ProCom One, Inc., San Marcos, 6,103,219 A 8, 2000 Sherwood et al. TX (US) 6,106,865 A 8, 2000 Staniforth et al. 6,211,229 B1 4/2001 Kavey (72) Inventors: Roberta L. Rogowski, Rancho Santa 6,217,907 B1 4/2001 Hunter et al. Fe, CA (US); Susan E. Dubé, Carlsbad, 6,217.909 B1 4/2001 Sherwood et al. CA (US); Philip Jochelson, San Diego, 6,219,674 B1 4/2001 Classen CA (US); Neil B. Kavey, Chappaqua, 6,344,487 B1 2/2002 Kavey 6,358,533 B2 3/2002 Sherwood et al. NY (US) 6,391,337 B2 5, 2002 Hunter et al. (73) Assignees: Pernix Sleep, Inc., Morristown, NJ 6,395,303 B1 5, 2002 Staniforth et al. (US); ProCom One, Inc., San Marcos, 6,403,597 B1 6/2002 Wilson et al. 6,407,128 B1 6/2002 Scaife et al. TX (US) 6,471.994 B1 10/2002 Staniforth et al. 6,521,261 B2 2/2003 Sherwood et al. (*) Notice: Subject to any disclaimer, the term of this 6,584,472 B2 6/2003 Classen patent is extended or adjusted under 35 6,683,102 B2 1/2004 Scaife et al.
    [Show full text]
  • Drug-Facilitated Sexual Assault in the U.S
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Estimate of the Incidence of Drug-Facilitated Sexual Assault in the U.S. Document No.: 212000 Date Received: November 2005 Award Number: 2000-RB-CX-K003 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. AWARD NUMBER 2000-RB-CX-K003 ESTIMATE OF THE INCIDENCE OF DRUG-FACILITATED SEXUAL ASSAULT IN THE U.S. FINAL REPORT Report prepared by: Adam Negrusz, Ph.D. Matthew Juhascik, Ph.D. R.E. Gaensslen, Ph.D. Draft report: March 23, 2005 Final report: June 2, 2005 Forensic Sciences Department of Biopharmaceutical Sciences (M/C 865) College of Pharmacy University of Illinois at Chicago 833 South Wood Street Chicago, IL 60612 ABSTRACT The term drug-facilitated sexual assault (DFSA) has been recently coined to describe victims who were given a drug by an assailant and subsequently sexually assaulted. Previous studies that have attempted to determine the prevalence of drugs in sexual assault complainants have had serious biases. This research was designed to better estimate the rate of DFSA and to examine the social aspects surrounding it. Four clinics were provided with sexual assault kits and asked to enroll sexual assault complainants.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,937,074 B2 Meyer (45) Date of Patent: Jan
    US008937074 B2 (12) United States Patent (10) Patent No.: US 8,937,074 B2 Meyer (45) Date of Patent: Jan. 20, 2015 (54) ENHANCEMENT OF THE ACTION OF 9/4866 (2013.01); A61K 31/133 (2013.01); ANT-INFECTIVE AGENTS AND OF A6 IK3I/4409 (2013.01); A61 K3I/496 CENTRAL AND PERPHERAL NERVOUS (2013.01); A61 K3I/4965 (2013.01); A61 K SYSTEMIAGENTS ANDTRANSPORTATION 38/02 (2013.01); A61 K39/39533 (2013.01); OF NUCLECACID SUBSTANCES CI2N 15/63 (2013.01) USPC ........................................ 514/256; 514/258.1 (71) Applicant: North West University, Potchefstroom (58) Field of Classification Search (ZA) None See application file for complete search history. (72) Inventor: Petrus Johannes Meyer, George (ZA) (56) References Cited (73) Assignee: North West University, Potchefstroom (ZA) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 5,633,284 A 5/1997 Meyer patent is extended or adjusted under 35 6,416.740 B1* 7/2002 Unger .......................... 424,952 U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 13/709,596 DE 2647 671 A1 4f1978 WO 9606152 A2 2, 1996 (22) Filed: Dec. 10, 2012 * cited by examiner (65) Prior Publication Data Primary Examiner — Alton Pryor US 2013/0336990 A1 Dec. 19, 2013 (74) Attorney, Agent, or Firm — Rothwell, Figg, Ernst & Manbeck, P.C. Related U.S. Application Data (63) Continuation of application No. 10/345.204, filed on (57) ABSTRACT Jan. 16, 2003, now Pat. No. 8,329,685, which is a The invention provides a method of enhancing the action of a continuation-in-part of application No.
    [Show full text]
  • Psychotropic Medication Policy
    New Jersey Department of Children and Families Office of Child Health Services Psychotropic Medication Policy January 14, 2010 (Revised May 17, 2011) Allison Blake, PhD LSW Commissioner NJ Department of Children and Families 1 Introduction Children have the right to safety, respect, justice, education, health and well-being. As a society we have the obligation to protect these values for all of our children. When children have been removed from their primary homes, whether due to abuse, neglect or other reasons, the state assumes the primary responsibility to safeguard these rights for the children in their care. The Department of Children and Families (DCF) is New Jersey’s state child welfare agency. Through direct services and community contracts DCF is focused on strengthening families and achieving safety, well-being and permanency for all New Jersey's children. The Department’s core values include safety, permanency and well-being. The Division of Youth and Family Services ensures children’s safety and works to promote the ability of families to maintain children’s safety within their own homes. The Division of Child Behavioral Health Services contracts for and coordinates a range of services that provide behavioral health services to all children in New Jersey according to their needs. The DCF Office of Child Health Services works with DYFS and DCBHS to ensure that children served by the Department receive high quality, coordinated services to meet their health care needs and assure their well-being. Children and youth with psychiatric illness have the same right to treatment as children and youth with any other health care need.
    [Show full text]
  • Spectrofluorimetric Determination of Doxepin Hydrochloride In
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Arabian Journal of Chemistry (2016) 9, S1177–S1184 King Saud University Arabian Journal of Chemistry www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Spectrofluorimetric determination of doxepin hydrochloride in commercial dosage forms via ion pair complexation with alizarin red S Nafisur Rahman *, Asma Khatoon Analytical Chemistry Division, Department of Chemistry, Aligarh Muslim University, Aligarh 202 002, Uttar Pradesh, India Received 29 July 2011; accepted 7 January 2012 Available online 17 January 2012 KEYWORDS Abstract A simple and sensitive spectrofluorimetric method has been developed for the determina- Pharmaceutical prepara- tion of doxepin hydrochloride in pharmaceutical preparations. It is based on the formation of tions; ion-pair complex between doxepin and alizarin red S at pH 3.09. The ion pair complex was Spectrofluorimetric method; extracted in dichloromethane and the fluorescence intensity was measured at 560 nm after excita- Ion-pair complex tion at 490 nm. The optimum conditions for determination were also investigated. The linear range and detection limit were found to be 2–14 and 0.55 lg/ml, respectively. The method has been successfully applied for the analysis of drug in commercial dosage forms. No interference was observed from common pharmaceutical adjuvant. Statistical comparison of the results obtained by the proposed method with that of the reference method shows excellent agreement and indicates no significant difference in accuracy and precision. ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
    [Show full text]
  • Synthesis, Characterization and Pharmacological Evaluation of Structurally Related Compounds of Dibenzoxepin and Dibenzothiepin M.L
    M.L. Lal Prasanth. Int. Res. J. Pharm. 2014, 5 (3) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article SYNTHESIS, CHARACTERIZATION AND PHARMACOLOGICAL EVALUATION OF STRUCTURALLY RELATED COMPOUNDS OF DIBENZOXEPIN AND DIBENZOTHIEPIN M.L. Lal Prasanth* Ezhuthachan College of Pharmaceutical Sciences, Neyattinkara, Thiruvananthapuram, Kerala, India *Corresponding Author Email: [email protected] Article Received on: 10/01/14 Revised on: 01/02/14 Approved for publication: 02/03/14 DOI: 10.7897/2230-8407.050348 ABSTRACT This study was designed to synthesize, characterize and to evaluate the pharmacological activity of Dibenzoxepin and Dibenzothiepin derivatives. Totally three compounds, two Dibenzoxepin derivatives and one Dibenzothiepin derivative were synthesized by conventional method. Purity of the synthesized compounds was ascertained by TLC and melting point determination by open capillary tube method and they were characterized by IR and NMR spectroscopic methods. Antidepressant activity of all the synthesized compounds was evaluated by despair swim test by using Swiss albino mice. Standard drug Imipramine was used as the control. In the results of the spectral study, all the compounds showed characteristic peak in IR and NMR spectroscopy. In the despair swim test, all the synthesized derivatives showed antidepressant activity. Among them one compound (PC158) showed significant antidepressant activity comparing with control drug imipramine. These results are useful for the further investigation in the future. Keywords: Antidepressant activity, Dibenzoxepin and Dibenzothiepin derivatives, Despair swim test, Swiss albino mice INTRODUCTION complete recovery or induce unwanted side effects. So there Depression is a serious medical issue characterized by a is still a large unmet clinical need7-9.
    [Show full text]
  • SINEQUAN® (Doxepin Hcl) CAPSULES ORAL CONCENTRATE
    SINEQUAN® (doxepin HCl) CAPSULES ORAL CONCENTRATE Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Sinequan or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Sinequan is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use) DESCRIPTION SINEQUAN® (doxepin hydrochloride) is one of a class of psychotherapeutic agents known as dibenzoxepin tricyclic compounds. The molecular formula of the compound is C19H21NO•HCl having a molecular weight of 316. It is a white crystalline solid readily soluble in water, lower alcohols and chloroform. Inert ingredients for the capsule formulations are: hard gelatin capsules (which may contain Blue 1, Red 3, Red 40, Yellow 10, and other inert ingredients); magnesium stearate; sodium lauryl sulfate; starch.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,532.971 B2 Schioppi Et Al
    USO09532971B2 (12) United States Patent (10) Patent No.: US 9,532.971 B2 Schioppi et al. (45) Date of Patent: Jan. 3, 2017 (54) LOW-DOSE DOXEPINFORMULATIONS 5,116,852 A 5/1992 Gammans AND METHODS OF MAKING AND USING 5,332,661 A 7, 1994 Adamczyk et al. 5,502,047 A 3/1996 Kavey THE SAME 5,585,115 A * 12/1996 Sherwood et al. ........... 424/489 5,643,897 A 7/1997 Kavey (71) Applicant: Pernix Sleep, Inc., Morristown, NJ 5,725,883 A 3, 1998 Staniforth et al. (US) 5,725,884 A 3, 1998 Sherwood et al. 5,733,578 A 3, 1998 Hunter et al. 5,741,524 A 4/1998 Staniforth et al. (72) Inventors: Luigi Schioppi, Escondido, CA (US); 5,858.412 A 1/1999 Staniforth et al. Brian Talmadge Dorsey, Encinitas, CA 5,866,166 A 2f1999 Staniforth et al. (US); Michael Skinner, San Diego, CA 5.948,438 A 9, 1999 Staniforth et al. (US); John Carter, Keswick (CA); 5,965,166 A 10, 1999 Hunter et al. Robert Mansbach, San Diego, CA 6,103,219 A 8, 2000 Sherwood et al. 6,106,865 A 8, 2000 Staniforth et al. (US); Philip Jochelson, San Diego, CA 6,211,229 B1 4/2001 Kavey (US); Roberta L. Rogowski, Rancho 6,217,907 B1 4/2001 Hunter et al. Santa Fe, CA (US); Cara Baron 6,217.909 B1 4/2001 Sherwood et al. Casseday, San Diego, CA (US); 6,219,674 B1 4/2001 Classen Meredith Perry, San Diego, CA (US); 6,344,487 B1 2/2002 Kavey 6,358,533 B2 3/2002 Sherwood et al.
    [Show full text]